{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:46:50Z","timestamp":1791946010436,"version":"4.3.4"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2024,3,1]]},"abstract":"\n Importance<\/jats:title>\n Currently there is no standard therapy to improve cancer-related anorexia, hampering survival. Mirtazapine has been suggested as a feasible option in this context.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To assess the effect of mirtazapine on appetite and energy consumption in patients with advanced non\u2013small cell lung cancer (NSCLC).<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This randomized, double-blind, placebo-controlled clinical trial including adults was performed in a tertiary cancer care center from August 2018 to May 2022 with a follow-up of 8 weeks. Overall, 134 patients were screened; 114 were assessed for eligibility and 28 were excluded.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Patients were randomized in a 1:1 ratio to receive mirtazapine, 15 mg, or placebo for 2 weeks followed by a dose escalation to 30 mg until week 8 or placebo. Both groups received nutritional assessment and dietary advice.<\/jats:p>\n <\/jats:sec>\n \n Main outcomes and measures<\/jats:title>\n Appetite was assessed by the Anorexia Cachexia Scale and energy intake. Dietary parameters were evaluated at baseline, 4 weeks, and 8 weeks, with a 24-hour dietary recall, and energy quantification based on the Mexican system of nutritional equivalents.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 86 patients met the inclusion criteria and were randomized to the placebo (n\u2009=\u200943) or the mirtazapine group (n\u2009=\u200943). Of these, 71 received the allocated intervention, and the mean (SD) age was 63.5 (11.2) years, 41 were women (57.7%), and 63 (88.7%) had adenocarcinoma, 63 (88.7%) had Eastern Cooperative Oncology Group performance status scale score of 1, 64 (90.1%) had stage IV NSCLC, and 50 (70.4%) were receiving first-line treatment. Baseline characteristics were similar between groups. There was no difference in appetite scores in patients who received mirtazapine or placebo after 4 and 8 weeks. After 4 weeks, mirtazapine significantly increased energy intake (379.3 kcal; 95% CI, 182.6-576.1;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) including proteins (22.5 g; 95% CI, 11.5-33.4;\n P<\/jats:italic>\n \u2009=\u2009.001), carbohydrates (43.4 g; 95% CI, 13.1-73.8;\n P<\/jats:italic>\n \u2009=\u2009.006), and fats (13.2 g; 95% CI, 6.0-20.4;\n P<\/jats:italic>\n \u2009=\u2009.006). Fats intake was significantly higher in patients in the mirtazapine group (14.5 g vs 0.7 g;\n P<\/jats:italic>\n \u2009=\u2009.02) after 8 weeks. The mirtazapine group significantly decreased the proportion of patients with sarcopenia (82.8% vs 57.1%,\n P<\/jats:italic>\n \u2009=\u2009.03) at 8 weeks. Patients on mirtazapine tolerated the treatment well, but reported a higher perception of nightmares at 2 weeks based on a 10 cm VAS score (0 [25th-75th percentile, 0-1] vs 0 [25th-75th percentile, 0-0] in the control group;\n P<\/jats:italic>\n \u2009=\u2009.009) but this finding was nonsignificant after 4 and 8 weeks.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion and Relevance<\/jats:title>\n In this randomized clinical trial of patients with advanced NSCLC, there was no difference in appetite scores in all patients who received mirtazapine or placebo, but the mirtazapine group had a significant increase in energy intake through the 4- and 8-week follow-up, mainly in fat intake, which is a better and crucial source of energy. The addition of mirtazapine in the treatment of patients with advanced NSCLC and anorexia may help these patients achieve their energy requirements and improve health-related quality of life, specifically emotional and cognitive functioning.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT04748523<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoncol.2023.5232","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T11:00:57Z","timestamp":1704970857000},"page":"305","source":"Crossref","is-referenced-by-count":42,"title":["Mirtazapine as Appetite Stimulant in Patients With Non\u2013Small Cell Lung Cancer and Anorexia"],"prefix":"10.1001","volume":"10","author":[{"given":"Oscar","family":"Arrieta","sequence":"first","affiliation":[{"name":"Thoracic Oncology Unit, National Cancer Institute of Mexico, Tlalpan, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"C\u00e1rdenas-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Nutrition department of Thoracic Oncology Unit, National Cancer Institute of Mexico, Tlalpan, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Rodriguez-Mayoral","sequence":"additional","affiliation":[{"name":"Palliative Care department, National Cancer Institute of Mexico, Tlalpan, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Gutierrez-Torres","sequence":"additional","affiliation":[{"name":"Radiotherapy department, National Cancer Institute of Mexico, Tlalpan, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Casta\u00f1ares","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Unit, National Cancer Institute of Mexico, Tlalpan, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Flores-Estrada","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Unit, National Cancer Institute of Mexico, Tlalpan, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Reyes","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Unit, National Cancer Institute of Mexico, Tlalpan, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Unit, National Cancer Institute of Mexico, Tlalpan, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Barrag\u00e1n","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Unit, National Cancer Institute of Mexico, Tlalpan, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Soberanis Pina","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Unit, National Cancer Institute of Mexico, Tlalpan, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres F.","family":"Cardona","sequence":"additional","affiliation":[{"name":"Treatment and research Center, C.T.I.C, Bogot\u00e1, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny G.","family":"Turcott","sequence":"additional","affiliation":[{"name":"Nutrition department of Thoracic Oncology Unit, National Cancer Institute of Mexico, Tlalpan, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"coi230068r1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.21149\/10660","article-title":"[Lung cancer. epidemiology, diagnosis and treatment].","volume":"61","author":"Arrieta","year":"2019","journal-title":"Salud Publica Mex"},{"issue":"3","key":"coi230068r2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"coi230068r3","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.102895","article-title":"Lung cancer in never smokers: the role of different risk factors other than tobacco smoking.","volume":"148","author":"Corrales","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"coi230068r4","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1080\/01635581.2018.1506488","article-title":"FAACT-Anorexia Cachexia Scale: cutoff value for anorexia diagnosis in advanced non-small cell lung cancer patients.","volume":"71","author":"Turcott","year":"2019","journal-title":"Nutr Cancer"},{"issue":"4","key":"coi230068r5","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/nutrit\/nuab045","article-title":"Appetite stimulants for patients with cancer: current evidence for clinical practice.","volume":"80","author":"Turcott","year":"2022","journal-title":"Nutr Rev"},{"issue":"1","key":"coi230068r6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/1759-7714.12910","article-title":"Updates on the pathogenesis of advanced lung cancer-induced cachexia.","volume":"10","author":"Zhu","year":"2019","journal-title":"Thorac Cancer"},{"issue":"3","key":"coi230068r7","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1177\/1534735418781743","article-title":"Lung cancer cachexia: can molecular understanding guide clinical management?","volume":"17","author":"S\u00f8rensen","year":"2018","journal-title":"Integr Cancer Ther"},{"issue":"21","key":"coi230068r8","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1200\/JCO.20.00611","article-title":"Management of cancer cachexia: ASCO Guideline.","volume":"38","author":"Roeland","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"coi230068r9","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1007\/s00520-018-4154-9","article-title":"The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial.","volume":"26","author":"Turcott","year":"2018","journal-title":"Support Care Cancer"},{"issue":"3","key":"coi230068r10","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/cncr.31128","article-title":"Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04).","volume":"124","author":"Katakami","year":"2018","journal-title":"Cancer"},{"issue":"4","key":"coi230068r11","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","article-title":"Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials.","volume":"17","author":"Temel","year":"2016","journal-title":"Lancet Oncol"},{"issue":"11","key":"coi230068r12","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1007\/s00520-008-0425-1","article-title":"Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine.","volume":"16","author":"Cankurtaran","year":"2008","journal-title":"Support Care Cancer"},{"issue":"3","key":"coi230068r13","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.21873\/anticanres.16277","article-title":"Effect of mirtazapine for the prevention of nausea and vomiting in patients with thoracic cancer receiving platinum-based chemotherapy.","volume":"43","author":"Kinomura","year":"2023","journal-title":"Anticancer Res"},{"issue":"7","key":"coi230068r14","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1002\/jpen.2385","article-title":"Markers of respiratory function response to high-carbohydrate and high-fat intake in patients with lung diseases: a systematic review with meta-analysis of randomized clinical trials.","volume":"46","author":"Guerra","year":"2022","journal-title":"JPEN J Parenter Enteral Nutr"},{"issue":"2","key":"coi230068r15","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1177\/1049909109345685","article-title":"Phase II trial of mirtazapine for cancer-related cachexia and anorexia.","volume":"27","author":"Riechelmann","year":"2010","journal-title":"Am J Hosp Palliat Care"},{"issue":"6","key":"coi230068r16","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.jpainsymman.2021.05.017","article-title":"Mirtazapine in cancer-associated anorexia and cachexia: a double-blind placebo-controlled randomized trial.","volume":"62","author":"Hunter","year":"2021","journal-title":"J Pain Symptom Manage"},{"issue":"5","key":"coi230068r17","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/S0885-3924(02)00381-0","article-title":"An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms.","volume":"23","author":"Theobald","year":"2002","journal-title":"J Pain Symptom Manage"},{"issue":"14","key":"coi230068r18","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1200\/JCO.22.01997","article-title":"Randomized double-blind placebo-controlled study of olanzapine for chemotherapy-related anorexia in patients with locally advanced or metastatic gastric, hepatopancreaticobiliary, and lung cancer.","volume":"41","author":"Sandhya","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"coi230068r19","first-page":"1779","article-title":"[Efficacy of mirtazapine for appetite loss and nausea of the cancer patient\u2013from clinical experience in Memorial Sloan-Kettering Cancer Center].","volume":"36","author":"Ito","year":"2009","journal-title":"Gan To Kagaku Ryoho"},{"issue":"3","key":"coi230068r20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/1060028018802816","article-title":"Efficacy and safety of appetite-stimulating medications in the inpatient setting.","volume":"53","author":"Howard","year":"2019","journal-title":"Ann Pharmacother"},{"issue":"5","key":"coi230068r21","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1080\/01635581.2020.1769691","article-title":"The role of a cachexia grading system in patients with non-small cell lung cancer treated with immunotherapy: implications for survival.","volume":"73","author":"Turcott","year":"2021","journal-title":"Nutr Cancer"},{"issue":"8","key":"coi230068r22","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1634\/theoncologist.2015-0058","article-title":"Nutritional status, body surface, and low lean body mass\/body mass index are related to dose reduction and severe gastrointestinal toxicity induced by afatinib in patients with non-small cell lung cancer.","volume":"20","author":"Arrieta","year":"2015","journal-title":"Oncologist"},{"issue":"2","key":"coi230068r23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/01635581.2016.1144075","article-title":"Value: changes in the detection and recognition thresholds of three basic tastes in lung cancer patients receiving cisplatin and paclitaxel and its association with nutritional and quality of life parameters.","volume":"68","author":"Turcott","year":"2016","journal-title":"Nutr Cancer"},{"issue":"2","key":"coi230068r24","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1080\/01635581.2019.1633362","article-title":"Baseline dysgeusia in chemotherapy-na\u00efve non-small cell lung cancer patients: association with nutrition and quality of life.","volume":"72","author":"Turcott","year":"2020","journal-title":"Nutr Cancer"},{"issue":"3","key":"coi230068r25","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1016\/j.jpainsymman.2011.05.002","article-title":"Intolerance to mirtazapine in advanced cancer.","volume":"42","author":"Davis","year":"2011","journal-title":"J Pain Symptom Manage"},{"issue":"5","key":"coi230068r26","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.gerinurse.2019.08.012","article-title":"Should mirtazapine be used to improve appetite and reverse weight loss?","volume":"40","author":"Simonson","year":"2019","journal-title":"Geriatr Nurs"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2813830\/jamaoncology_arrieta_2024_oi_230068_1769036002.79301.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T16:00:17Z","timestamp":1769097617000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2813830"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2023.5232","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,1]]}}}